According to Nova One Advisor, the global viral vector & plasmid DNA manufacturing size is calculated at USD 7.54 billion in 2025 and is expected to surpass around USD 27.71 billion by 2034, growing ...
Computational tool improves recombinant virus design efficiency and yield.This innovative in-house development is a key component of Transgene’s ...
Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...
Contract development and manufacturing organization (CDMO) Matica Biotechnology has partnered with Calidi Biotherapeutics to ...
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing ...
Comprehensive immunogenicity data of individualized neoantigen therapeutic vaccine (INTV) TG4050, from the randomized Phase I study in operable ...
AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side ...
Gene therapy offers the possibility of addressing cancer at its molecular roots by targeting disease-causing genes rather than relying solely on surgery, chemotherapy, or radiotherapy. Among RNA-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback